Ann Clin Case Rep | Volume 7, Issue 1 | Research Article | Open Access
Mebrouk N*, El Hafidi N, Benbrahim F, Jaabouti R, Benchekroun S and Mahraoui C
Department of Pediatric Pneumology and Infectious Diseases, Rabat Children's Hospital, Mohammed V University, MoroccoFulltext PDF
Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but serious complication that affects some children a few weeks after SARS-CoV-2 infection. The similarities of MIS-C with Kawasaki Disease (KD) and Macrophage Activation Syndrome (MAS) suggest that the syndrome represents a spectrum of diseases. MIS-C, which is initiated by an overactive immune response in children, puts pressure on the heart, as inflamed blood vessels become incapable of carrying adequate blood, hence producing cardiac complications. Here we describe the clinical and laboratory characteristics of 23 patients who were admitted to our unit and diagnosed with MIS-C. The outcome was favorable for all patients after receiving treatment with a combination of Intravenous Immunoglobulin (IVIG), aspirin, and, for some patients, a corticosteroid. Only one patient required intensive-unit care. The average hospital stay was 7 days, and no mortality occurred. For some patients, MIS-C’s unopposed inflammatory state progresses rapidly to multiorgan failure. Cardiovascular complications consisting of shock, myocarditis, decreased cardiac function, and coronary artery dilatation was noted in 43% of the patients in our study. The goal of our study is to identify clinical features and laboratory results, if any, associated with severe clinical outcomes of MIS-C. Such information would help in the decision to initiate targeted immunotherapy quickly.
Multisystem Inflammatory Syndrome in Children (MIS-C); Pediatric Inflammatory Multisystem Syndrome (PIMS); Hyperinflammatory shock; Severe Acute Respiratory Syndrome 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID 19); Children; Pediatric
Mebrouk N, El Hafidi N, Benbrahim F, Jaabouti R, Benchekroun S, Mahraoui C. Factors Associated with Severe Outcomes in Multisystem Inflammatory Syndrome in Children: A Retrospective Study from Morocco. Ann Clin Case Rep. 2022; 7: 2170..